Accéder au contenu
Merck
Toutes les photos(1)

Documents

V-022

Supelco

Vigabatrin solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C6H11NO2
Poids moléculaire :
129.16
Numéro CE :
200-659-6
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

NC(CCC(O)=O)C=C

InChI

1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

Clé InChI

PJDFLNIOAUIZSL-UHFFFAOYSA-N

Informations sur le gène

human ... ABAT(18)

Catégories apparentées

Description générale

Vigabatrin is a newer antiepileptic sold as Sabril® in the US, Canada, Mexico and the United Kingdom and as Sabrilex in Denmark. The drug is used as an adjunctive treatment of complex partial seizures in adults and for infantile spasms in pediatric patients one month to two years of age. This certified Snap-N-Spike® Solution standard is suitable for use in LC/MS or GC/MS applications including forensic analysis, clinical toxicology, urine drug testing, or pharmaceutical research.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Sabril is a registered trademark of Lundbeck LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 4

1 of 4

Rufinamide ≥98% (HPLC), powder

Sigma-Aldrich

R8404

Rufinamide

Lorazepam solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-901

Lorazepam solution

α-Hydroxymidazolam solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

H-902

α-Hydroxymidazolam solution

Midazolam solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-908

Midazolam solution

The potential value of a negative finding: an illustrative example.
Kenneth Silverman et al.
JAMA psychiatry, 70(6), 571-572 (2013-04-12)
Peter Weber et al.
Epilepsy & behavior : E&B, 24(1), 138-140 (2012-04-17)
We report the case of an adolescent girl who suffered from symptomatic refractory focal epilepsy after an arteria cerebri media insult 15 years prior to this report. Five weeks after initiation of an add-on therapy with vigabatrin, she was seizure
O Heinzlef et al.
Revue neurologique, 168 Suppl 3, S62-S68 (2012-06-29)
The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol. However, spasticity may not be uncomfortable and may even be useful. Therefore, all spastic diseases do
Lisa M Clayton et al.
Ophthalmology, 119(10), 2152-2160 (2012-08-03)
To explore the relationship of peripapillary retinal nerve fiber layer (ppRNFL) thinning in individuals exposed to the antiepileptic drug vigabatrin with respect to 2 separate variables: cumulative vigabatrin exposure and severity of vigabatrin-associated visual field loss (VAVFL). Cross-sectional observational study.
C Y Go et al.
Neurology, 78(24), 1974-1980 (2012-06-13)
To update the 2004 American Academy of Neurology/Child Neurology Society practice parameter on treatment of infantile spasms in children. MEDLINE and EMBASE were searched from 2002 to 2011 and searches of reference lists of retrieved articles were performed. Sixty-eight articles
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique